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Background: A meta-analysis was conducted to assess the safety and efficacy of biodegradable polymer
drug-eluting stents (BP-DESs).
Methods: PubMed, Science Direct, China National Knowledge Infrastructure, and Chongqing VIP databases were
searched for randomized controlled trials comparing the safety and efficacy of BP-DESs versus durable polymer
drug-eluting stents (DP-DESs). Efficacy included the prevalence of target lesion revascularization (TLR), target vessel
revascularization (TVR), and late lumen loss (LLL), and safety of these stents at the end of follow-up for the selected
research studies were compared.
Results: A total of 16 qualified original studies that addressed a total of 22,211 patients were included in this
meta-analysis. In regard to efficacy, no statistically significant difference in TLR (odds ratio (OR) = 0.94, P = 0.30) or
TVR (OR 1.01, P = 0.86) was observed between patients treated with BP-DESs and those with DP-DESs. However,
there were significant differences in in-stent LLL (weighted mean difference [WMD] = −0.07, P = 0.005) and in-segment
LLL (WMD= −0.03, P = 0.05) between patients treated with BP-DESs and with DP-DESs. In terms of safety, there was no
significant difference in overall mortality (OR 0.97, P = 0.67), cardiac death (OR 0.99, P = 0.90), early stent thrombosis
(ST) and late ST (OR 0.94, P = 0.76; OR 0.96, P = 0.73), or myocardial infarction (MI) (OR 0.99, P = 0.88) between patients
treated with BP-DESs and with DP-DESs. However, there was a statistically significant difference in very late ST (OR 0.69,
P = 0.007) between these two groups. In addition, the general trend of the rates of TVR and TLR of BP-DESs groups was
lower than DP-DESs groups after a 1-year follow-up.
Conclusion: BP-DESs are safe, efficient, and exhibit superior performance to DP-DESs with respect to reducing the
occurrence of very late ST and LLL. The general trend of the rates of TVR and TLR of BP-DESs groups was lower than
DP-DESs groups after a 1-year follow-up.
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Recent discoveries in medical technology and bioengin-
eering have led to substantial advancements in the
design of coronary stents, particularly in lowering the
rates of restenosis occurrence after percutaneous coron-
ary stenting with drug-eluting stents (DESs) rather than
after percutaneous coronary stenting with bare metal
stents (BMSs) [1]. A large number of studies have dem-
onstrated that the presence of a non-degradable polymer
in the coronary arteries after prolonged drug release can
cause inflammatory responses in local vessel walls and
delay the healing of the vascular endothelium [2-4].
These issues may be the primary causes of postoperative
stent thrombosis and late stenosis following the implant-
ation of permanent durable polymer drug-eluting stents
(DP-DESs) [5,6]. It has been proven that the implant-
ation of a first-generation DP-DES instead of a BMS can
decrease both the incidence of restenosis and target le-
sion revascularization after percutaneous coronary inter-
vention (PCI) [7]. The underlying mechanism leading to
restenosis is an excessive local vascular healing response
to balloon and stent injury; this response stimulates the
release of a variety of growth factors and cytokines,
causing vascular smooth muscle cell and intimal prolif-
eration and thereby resulting in the thickening of blood
vessel walls [8]. A coating of antiproliferative drugs and
polymers on the stent will not only inhibit the prolifera-
tion and migration of smooth muscle cells but also affect
the function of endothelial cells. This effect can result in
the poor healing of stent-injured vascular segments;
moreover, the long-term presence of a permanent poly-
mer stent coating can produce a persistent inflammatory
response. This inflammation can cause the proliferation
of endothelial cells in stented vessel segments, resulting
in restenosis. The recent invention of BP-DESs can solve
this issue; in particular, the complete degradation of the
polymer coating of BP-DESs will ensure that BP-DESs
cause significantly lower levels of long-term structural
damage and chronic inflammation than DP-DESs that
feature a permanent polymer coating.
A new generation of BP-DESs has been developed that
exhibit good potential applicability because they not only
effectively deliver drugs to patients but will also com-
pletely degrade into harmless compounds such as water,
and carbon dioxide after drug release has been com-
pleted [9].
Relative to the use of BMSs, the use of DESs and
polymer-free DESs can produce significantly lower
restenosis rates after PCI; thus, the development of DESs
constitutes a milestone in the field of interventional
cardiology. Although the use of DESs instead of BMSs
can significantly improve the therapeutic efficacy of PCI
treatments, previous studies have reported that com-
pared to implantation of BMSs, the implantation ofDESs produces significantly higher incidences of adverse
events, such as stent thrombosis (ST) [10]. The inci-
dence of ST is relatively low; nonetheless, this issue has
attracted widespread concern because the consequences
of ST are extremely serious [11,12]. Moreover, investiga-
tions have indicated that the presence of a DES may
delay vascular endothelial healing and that the perman-
ent residues left by non-degradable polymers from such
stents may trigger an inflammatory response in local
vessel walls; these phenomena are closely related to se-
vere adverse reactions to DESs [13,14]. Over time, the
drug-coated polymers of BP-DESs can gradually degrade
into completely harmless CO2 and H2O molecules that
are excreted from a patient’s body. In this manner, a BP-
DES can completely transform into a BMS following a
slow, controlled drug release. Thus, relative to DP-DESs,
BP-DESs can reduce drug-induced delays in vascular
endothelialization and inflammatory responses of local
vessel walls caused by the presence of a permanent poly-
mer, thereby achieving the dual purpose of preventing
both in-stent restenosis and late stent thrombosis [10].
Several previous studies regarding the efficacy and
safety of BP-DESs and DP-DESs have produced inconsist-
ent results [15-17]. However, as mentioned in another
paper, the major limitations of the previous meta-analyses
were that the variability of patients with newer-generation
DES were relatively small and thus comparisons had re-
stricted statistical power, and BP-DESs were not included
in the analyses. Even though, BP-DES is not approved in
the USA, they are still used worldwide including some
countries in Asia and Europe. Therefore, we conducted
this meta-analysis to compare the safety and efficacy of
these two types of stents, with the inclusion of Chinese re-
search studies on this topic.
Methods
Study design
A systematic literature search was performed to identify
randomized controlled studies (RCTs) assessing safety
and efficacy of BP-DESs and DP-DESs in accordance
with the recommended steps provided in the Cochrane
Handbook for Systematic Reviews of Interventions [18].
Results were systematically analyzed to determine the re-
lationship between treatment methods and its efficacy
and safety.
Database search
Electronic searches were performed using the electronic
databases provided by PubMed, Science Direct, China
National Knowledge Infrastructure, Chongqing VIP, and
other databases for relevant studies published between
December 1990 and December 2015. The literature
searches were conducted using the search terms “bio-
degradable polymer,” “drug-eluting,” “stent,” and “coronary
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“NOT,” and “OR”. The articles written in English and/or
Chinese language were included.
Study inclusion and exclusion criteria
The studies examined in this study were required to
fulfill the following inclusion criteria: (1) human study
subjects, (2) a randomized controlled design, relatively
complete study results, (4) a follow-up period of more
than 6 months, and (5) an experimental comparison be-
tween BP-DESs and DP-DESs with respect to safety and
efficacy. The following exclusion criteria were utilized
for the examined studies: (1) a non-randomized con-
trolled design, (2) incomplete data, the use of BMSs in a
control group, and (4) a repeated examination of the
same study population (in these cases, only the study
with the longest follow-up period was utilized). Studies
were selected in strict accordance with the inclusion and
exclusion criteria. All of the original reports for the
selected studies included specific diagnostic criteria, in-
clusion criteria for the examined cases, appropriate stat-
istical methods, explicit evaluation indicators, and clear
and complete data.
Data collection and outcome measurement
Two authors (Gang Wang and Mingli Wang) independ-
ently assessed all potentially relevant studies and reached
a consensus on all items. Any discrepancies were resolved
through discussion, with arbitration by a third author if







Chevalier [19] 2 2 1 0
Byrne [20] 2 2 2 1
Chevalier [21] 2 2 1 1
Stefanini [22] 2 2 2 1
Byrne [23] 2 2 2 1
Maamoun [24] 1 1 0 1
Kadota [25] 1 1 0 1
Xu [26] 1 1 2 0
Tan [27] 1 1 2 1
Ge [28] 1 1 0 1
Smits [29] 2 2 0 0
Zhang [30] 2 2 1 1
Natsuaki [31] 2 2 0 0
Raungaard [32] 2 2 0 0
Han [33] 2 1 1 1
Pilgrim [34] 2 2 2 0
MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revastudy: first author, publication year, characteristics of study
subjects, study design, outcomes for efficacy, and safety of
stents (Tables 1 and 2).
The included studies assessed indicators of the efficacy
and safety of stents. The efficacy indicators included the
prevalence of target lesion revascularization (TLR), tar-
get vessel revascularization (TVR), and late lumen loss
(LLL) (including both in-segment and in-stent LLL) dur-
ing the follow-up period. The safety indicators included
not only overall mortality and cardiac deaths but also
the prevalence of myocardial infarction (MI) and stent
thrombosis (ST) during follow-up periods.
Quality assessment
Eligible studies were evaluated for inclusion by two inde-
pendent reviewers (Xingmei Zhang and Li Zhang), and
the level of agreement between reviewers was recorded.
Inclusion of studies was determined by screening of man-
ual titles and abstracts, followed by full-text screening by
the same reviewers. The quality of each study was assessed
using the modified Jaded scale for study selection [35] (for
more detailed information, see Table 1). These scales were
used to evaluate randomized approach, allocation conceal-
ment, blinding, and lost to follow-up. In the event of in-
complete data, authors of potentially eligible studies were
contacted to obtain relevant unpublished data.
Statistical analysis
Review Manager (RevMan) 5.1 statistical software






5 Cardiac death, overall mortality, MI, TLR, TVR, ST, LLL
7 Overall mortality, MI, TLR, ST, LLL
6 Cardiac death, overall mortality, MI, TLR, TVR, ST, LLL
7 Cardiac death, overall mortality, MI, TLR, TVR, ST
7 Cardiac death, overall mortality, MI, TLR, ST
3 Cardiac death, overall mortality, MI, TLR, ST
3 Cardiac death, overall mortality, MI, TLR, TVR, ST, LLL
4 Cardiac death, overall mortality, MI, TLR, ST, LLL
5 Cardiac death, overall mortality, MI, TLR, TVR, ST
3 Cardiac death, MI, TVR, ST
4 Cardiac death, overall mortality, MI, TVR, TLR, ST
6 Cardiac death, overall mortality, MI, TVR, TLR, ST
4 Cardiac death, overall mortality, MI, TVR, TLR, ST
4 Cardiac death, overall mortality, MI, TVR, TLR, ST
5 Cardiac death, overall mortality, MI, TVR, TLR, ST
6 Cardiac death, overall mortality, MI, TVR, TLR, ST
scularization; ST, stent thrombosis; LLL, late lumen loss.
Table 2 The baseline characteristics of the included studies












Lesion length (mean ± SD) Reference diameter (mean ± SD)
BP DP BP DP BP DP
Chevalier [19] EuroInterv 2007 BES PES 120 6 9 65/63 69/66 18/26 56.47/68.57 11.35 ± 4.51 11.03 ± 4.75 2.70 ± 0.44 2.60 ± 0.57
Byrne [20] Heart 2009 SES SES 404 12 24 66.5/65 79.3/78.2 27.4/28.7 NA 13.9 ± 7.2 14.6 ± 7.0 2.74 ± 0.59 2.80 ± 0.52
Chevalier [21] Circ Cardiovasc
Intervent 2009
BES PES 243 6 9 62.7/63.2 74.5/68.9 16.3/27.8 49.67/44.44 10.56 10.84 2.72 2.73
Stefanini [22] Lancet 2011 BES SES 1,707 12 48 64.6/64.5 75.0/74.6 26.0/22.5 NA 15.2 ± 11.7 14.4 ± 10.6 2.60 ± 0.61 2.71 ± 0.52
Byrne [23] JACC 2011 SES EESSES 2,603 6 36 66.7/66.8 77.8/75.9 28.2/29.6 72.8/72.1 14.8 ± 8.6 15.0 ± 8.8 2.79 ± 0.47 2.75 ± 0.51
Maamoun [24] The Egyptian Heart
Journal 2012
BES SESPES 145 6 24 56.7/54.2 87.1/85.5 NA NA NA NA NA NA
Kadota [25] CCI 2012 BES SES 326 3 9 67.1/67.7 71.6/72.0 38.7/39.4 69.7/62.0 12.64 ± 5.52 12.82 ± 6.81 2.68 ± 0.57 2.68 ± 0.54
Xu [26] EuroInterv 2012 SES SES 300 12 24 56.6/56.7 66.7/72 22/20 47.0/41.7 17.74 ± 9.30 18.72 ± 9.98 NA NA
Tan [27] Chin J Clinicians 2012 BES EES 50 12 24 62/63 70.0/73.3 20.0/23.3 NA NA NA NA NA
Ge [28] JACC 2012 SES SES 1,909 12 12 63.3/62.1 67.7/73.0 20.5/20.75 NA NA NA NA NA
Smits [29] Lancet 2013 BES EES 2,707 12 12 63/62.7 74.4/74.3 21.8/21.6 63.7/63.3 16.8 ± 9.8 17.7 ± 10.6 2.9 ± 0.5 2.9 ± 0.5
Zhang [30] INT J CARDIOL 2013 SES SES 662 12 24 65.9/67.5 68.5/69.2 27.73/32.26 66.34/69.51 24.77 ± 14.47 29.20 ± 16.6 3.13 ± 0.45 3.26 ± 2.40
Natsuaki [31] JACC 2013 BES EES 3,235 3 12 69.1/69.3 77/77 46/46 NA 19.5 ± 12.8 19.3 ± 13.1 2.62 ± 0.6 2.61 ± 0.57
Raungaard [32] Lancet 2015 BES ZES 2,999 12 12 65.8/65.7 76.2/75.8 17.6/18.0 63/70 15.0 16.0 3.0 3.2
Han [33] JACC 2014 SES SES 2,737 6 12 60.2/60.2 68/70 22.6/21.3 83.5/85.1 20.6 ± 12.3 21.2 ± 12.9 2.79 ± 0.47 2.79 ± 0.44
Pilgrim [34] Lancet 2014 SES EES 2,119 12 12 66.1/65.9 77.0/77.3 24.2/21.7 NA 25.91 ± 15.40 27.45 ± 16.77 3.05 ± 0.49 3.03 ± 0.49
Notes: BP, bioabsorbable polymer drug-eluting stent; DP, durable polymer drug-eluting stent; NC, number of cases; DAPT, dual antiplatelet therapy; FU, follow-up period; BES, biolimus-eluting stent; SES, sirolimus-
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(OR) and weighted mean difference (WMD) statistics
were used for the analysis of efficacy-related count data
and measurement data, respectively. Additionally, 95%
confidence intervals (CIs) were provided for all efficacy
analyses, and forest plot was created. A funnel plot of the
included studies was created to detect the presence of
publication bias. The heterogeneity of the results of clin-
ical trials was assessed by the chi-square test. If these re-
sults were homogeneous (P > 0.1, I2 < 50%), fixed effects
models were utilized for meta-analyses, whereas if these
results were heterogeneous (P ≤ 0.1, I2 ≥ 50%), the causes
of this heterogeneity were assessed and a sensitivity ana-
lysis was performed. If heterogeneities in the results of
clinical trials could not be eliminated, random effects
models were used for meta-analyses or qualitative sys-
temic evaluations were conducted. A P value of ≤0.05 was
regarded as statistically significant.
Results and discussion
Literature search
A total of 961 original studies, including 882 English-
language publications and 79 Chinese publications, were
retrieved from internet searches of electronic databases.
However, 726 of these studies were excluded as irrele-
vant based on their titles and abstracts, 95 of these stud-
ies were excluded because they were non-(RCTs), and an
additional 72 of these studies were excluded becauseFigure 1 A flowchart of the literature review process.their control groups involved the utilization of non-
drug-eluting stents. Thus, 68 original studies were ini-
tially obtained. After 45 of these studies were excluded
due to either duplication or a lack of complete data, a
total of 23 studies were regarded as relevant investiga-
tions. Seven of these studies were excluded because they
involved examinations of the same population over
different follow-up periods. Eventually, 16 studies were
identified that fulfilled the study selection criteria (in-
cluding 15 English-language publications and 1 Chinese
publication) (Figure 1).
Characteristics of included studies
All of these included studies were randomized controlled
investigations that specified the number of studied cases
and the number of occurrences of MI. Out of the 16
chosen literature, 15 studies provided clear data re-
garding overall mortality and clear data regarding the
occurrence of ST and cardiac death. Fourteen studies
provided clear data regarding the occurrence of TLR,
12 studies provided clear data regarding the occur-
rence of TVR, and 6 studies provided clear data re-
garding the occurrence of LLL (Table 1). The selected
literature included one conference abstract; however,
detailed data regarding the study described by this ab-
stract were obtained in PowerPoint (ppt) format. Full-
text reports describing all of the remaining included
studies have been published. For all of the included
Lv et al. European Journal of Medical Research  (2015) 20:21 Page 6 of 12studies, there were no significant differences in the
baseline characteristics of the cases in the BP-DES and
the DP-DES groups (Table 2). The follow-up periods of
the studies examined in this investigation ranged from
6 to 48 months. The selected efficacy indicators in-
cluded TLR, TVR, and LLL (including both in-segment
and in-stent LLL); the selected safety indicators in-
cluded overall mortality, cardiac deaths, MI, and ST.
Efficacy analysis
There was no significant heterogeneity regarding the
occurrence of TLR and different times TLR among the 14
included studies that addressed this phenomenon (P = 0.45,
I2 = 0%; P = 0.14, I2 = 35%; P = 0.85, I2 = 0%); therefore, a
fixed effects model was used for the TLR-related meta-
analysis. There was no significant difference between the
BP-DES and DP-DES groups with respect to the occur-
rence of TLR during follow-up periods (OR 0.94, 95% CI
0.83 to 1.06, Z = 1.03, P = 0.30, Figure 2A). Also there wasFigure 2 Fixed effects model used for the TLR-related meta-analysis.
who received a BP-DES or a DP-DES. (B) The TVR forest plot for patients wi
(C) The total mortality forest plot for patients with coronary artery heart disno significant difference between the BP-DES and DP-DES
groups with respect to the occurrence of TLR during 1-
year and more than 1-year follow-up periods, but we found
the general trend of the rates of TLR of DP-DES groups
was significantly higher (OR 0.95, 95% CI 0.79 to 1.14,
Z = 0.58, P = 0.56; OR 0.88, 95% CI 0.74 to 1.05, Z = 1.41,
P = 0.16, Figure 3A, B).
There was no significant heterogeneity regarding the
occurrence of TVR and different times TVR among
the 12 included studies that addressed this phenomenon
(P = 0.39, I2 = 5%; P = 0.58, I2 = 0%; P = 0.76, I2 = 0%);
therefore, a fixed effects model was used for the TVR-
related meta-analysis. There was no significant difference
between the BP-DES and the DP-DES groups with respect
to the occurrence of TVR during follow-up periods (OR
1.01, 95% CI 0.88 to 1.17, Z = 0.18, P = 0.86, Figure 2B).
Also there was no significant difference between the BP-
DES and DP-DES groups with respect to the occurrence
of TVR during 1-year and more than 1-year follow-up(A) The TLR forest plot for patients with coronary artery heart disease
th coronary artery heart disease who received a BP-DES or a DP-DES.
ease who received a BP-DES or a DP-DES.
Figure 3 General trend of the rates of TVR and TLR of DP-DES. (A) The TLR forest plot for patients with coronary artery heart disease who
received a BP-DES or a DP-DES during 1 year. (B) The TLR forest plot for patients with coronary artery heart disease who received a BP-DES or a
DP-DES more than 1 year. (C) The TVR forest plot for patients with coronary artery heart disease who received a BP-DES or a DP-DES during 1 year.
(D) The TVR forest plot for patients with coronary artery heart disease who received a BP-DES or a DP-DES more than 1 year.
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of TVR of DP-DES was significantly higher (OR 1.00, 95%
CI 0.82 to 1.21, Z = 0.01, P = 0.99; OR 0.79, 95% CI 0.61 to
1.02, Z = 1.80, P = 0.07, Figure 3C, D).
There was a significant heterogeneity regarding in-
stent LLL among the six included studies that addressed
this phenomenon (P = 0.05, I2 = 56%); therefore, a ran-
dom effects model was used for the meta-analysis of in-
stent LLL. This meta-analysis revealed a significant dif-
ference between the BP-DES and DP-DES groups with
respect to in-stent LLL during follow-up periods (WMD
= −0.07, 95% CI −0.12 to −0.02, Z = 2.79, P = 0.005), sug-
gesting that in-stent LLL was significantly lower in the
BP-DES group than in the DP-DES group. The six in-
cluded studies were examined to assess in-segment LLL.
There was no significant heterogeneity among these
studies with respect to in-segment LLL (P = 0.69 > 0.1, I2
= 0%); therefore, a fixed effects model was used. In-segment LLL was significantly lower (WMD = −0.03,
95% CI −0.07 to −0.00, Z = 1.97, P = 0.05) in the BP-DES
group than in the DP-DES group. One set of relevant
studies that reported LLL data conducted repeated mea-
surements of the same population; the report from this
set of studies that involved the longest follow-up period
was selected as the included study for this investigation.
However, for the LLL analyses, the relevant data for this
population were instead obtained from a study with a
short follow-up period because the other LLL data of
this investigation were obtained from studies with rela-
tively short follow-up periods [36]. Details regarding the
LLL-related meta-analyses are provided in Figure 4A, B).
Safety analysis
There was no significant heterogeneity regarding total
mortality among the included studies that addressed
total mortality, cardiac deaths, MI events, occurrence of
Figure 4 Details regarding the LLL-related meta-analyses. (A) The in-stent LLL forest plot for patients with coronary artery heart disease who
received a BP-DES or a DP-DES. (B) The in-segment LLL forest plot for patients with coronary artery heart disease who received a BP-DES or
a DP-DES.
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I2 = 0%; P = 1.00, I2 = 0%; P = 0.47, I2 = 0%; P = 0.28,
I2 = 20%; P = 0.56, I2 = 0%; P = 0.45, I2 = 0%); therefore, a
fixed effects model was used for all these incidences.
There was no significant differences between the BP-DES
and DP-DES groups with respect to overall mortality (OR
0.93, 95% CI 0.79 to 1.09, Z = 0.92, P = 0.36, see Figure 2C),
cardiac deaths (OR 0.99, 95% CI 0.80 to 1.21, Z = 0.13,
P = 0.90, Figure 5A), MI events and (OR 1.02, 95% CI
0.86 to 1.21, Z = 0.22, P = 0.82, Figure 5B), occurrence of
ST (OR: 0.89, 95% CI: 0.72 to 1.09, Z = 1.16, P = 0.25,
Figure 5C) during follow-up periods. However, very late
ST (>12 months) was significantly lower in the BP-DES
group than in the DP-DES group (OR 0.69, 95% CI 0.52
to 0. 90, Z = 2.70, P = 0.007). Details regarding the differ-
ent times of ST-related meta-analyses are provided in
Figure 6A, B, C.
Publication bias analysis
Figure 7 is the funnel plot indicating MI among patients
with coronary artery heart disease who received a BP-
DES or DP-DES. As indicated by the plot, no publication
bias appeared to exist in the relevant studies.
We conducted meta-analyses of 16 RCTs; these studies
examined a total of 22,211 patients, including 12,368 pa-
tients treated with BP-DESs and 9,843 patients treated
with DP-DESs. Our study found no significant differ-
ences in cardiac death, overall mortality, MI, TLR, orTVR between patients treated with BP-DESs and pa-
tients treated with DP-DESs. However, the occurrence of
very late ST (>12 months) may be significantly reduced
by the use of BP-DESs instead of DP-DESs, and the gen-
eral trend of the rates of TVR and TLR of DP-DESs
groups was higher than BP-DESs groups after a 1-year
follow-up. In addition, LLL were significantly less likely
to occur in patients treated with BP-DESs than in pa-
tients treated with DP-DESs during follow-up periods.
Our meta-analysis included abundant outcome indica-
tors that can comprehensively reflect the efficacy of two
different types of stents. It also addressed various types
of BP-DESs, except for some specialized stent technolo-
gies (such as stents with reservoirs). As these stents are
not strictly BP-DESs, a similar meta-analysis by Lupi et al.
[37] excluded studies that addressed the use of specialized
stent technologies (such as stents with reservoirs) from
the original literature. Additionally, we included a few
Chinese studies in our meta-analysis for detailed assess-
ment and to reduce bias.
The results of this meta-analysis with respect to car-
diac death, overall mortality, and MI are consistent with
the findings from large-scale studies by Klauss et al. [38]
and Byrne et al. [39] who indicated that there were no
significant differences between BP-DESs and DP-DESs.
However, the use of BP-DESs instead of DP-DESs can
significantly reduce the incidence of both identified and
potential cases of ST, as defined by the US and European
Figure 5 Results of the BP-DES and DP-DES groups with respect to overall mortality. (A) The cardiac death forest plot for patients with
coronary artery heart disease who received a BP-DES or a DP-DES. (B) The MI forest plot for patients with coronary artery heart disease who received a
BP-DES or a DP-DES. (C) A stent thrombosis (ST) forest plot for patients with coronary artery heart disease who received a BP-DES or a DP-DES.
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of endothelialization is a factor that could increase the
risk of thrombosis. The persistent stimulation of
vascular endothelial cells by the permanent coating of
DP-DESs can significantly delay the postoperative re-
endothelialization of a target vessel after PCI, whereas
the biological coating of BP-DESs completely degrades
after the drug release process has completed, thus
reducing the stimulation of these endothelial cells. A
previous study has demonstrated that complete target
lesion re-endothelialization occurs in 28 days after
BMS implantation, but requires a significantly longer
period of about 90 to 180 days after DES implantation
[41]. The incidence of late ST is closely related to vari-
ous factors, including early antiplatelet treatment, the
extent of coronary artery lesions, and the quantity of
implanted coronary stents [42]. However, long-term
stimulation by permanent polymers is certainly an ex-
tremely important determinant of late ST.Additionally, LLL during follow-up periods was signifi-
cantly lower among patients treated with BP-DESs than
among patients treated with DP-DESs. LLL is determined
based on the difference between the minimum lumen
diameter (MLD) immediately after stent implantation and
the follow-up MLD after a follow-up period of at least
6 months.
To summarize, BP-DESs are safe and effective; addition-
ally, they may become a valid alternative to DP-DESs. The
incidence of ST increases after 1 year following the im-
plantation of a DES. The follow-up periods of the studies
examined in this investigation ranged from 6 to 48 months.
To incorporate additional clinical studies with long
follow-up times into meta-analyses of this topic and
thereby obtain more stable and reliable conclusions, it is
necessary to conduct additional large-scale rigorous RCTs
with lengthy follow-up durations.
This meta-analysis exhibited the following limitations.
(1) The included studies do not have identical follow-up
Figure 6 Details regarding the different times of ST-related meta-analyses. (A) The early ST forest plot for patients with coronary
artery heart disease who received a BP-DES or a DP-DES. (B) The late ST forest plot for patients with coronary artery heart disease who
received a BP-DES or a DP-DES. (C) The very late ST forest plot for patients with coronary artery heart disease who received a BP-DES or
a DP-DES.
Lv et al. European Journal of Medical Research  (2015) 20:21 Page 10 of 12periods; instead, the range of follow-up durations was
relatively broad (between 6 and 48 months). (2) The lim-
itations of the meta-analytical approach are well known
and documented; thus, the safety and efficacy of various
types of stents was not specifically identified [19].Figure 7 A funnel plot indicating stent thrombosis among patients w
a DP-DES.Conclusions
In conclusion, the meta-analysis results indicated that
the implantation of BP-DESs can effectively prevent the
incidence of mortality, cardiac death, MI, TLR, and other
adverse events. The use of BP-DESs instead of DP-DESsith coronary artery heart disease who received a BP-DES or
Lv et al. European Journal of Medical Research  (2015) 20:21 Page 11 of 12can decrease the incidence of very late ST and alleviate
LLL. In addition, the general trend of the rates of TVR
and TLR of DP-DESs groups was higher than BP-DESs
groups after a 1-year follow-up. To summarize, BP-DESs
are safe and effective.
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